BGI has secured its position at the forefront of life science corporate institutions in the Asia Pacific and China for the seventh straight year, as revealed in the 2022 Nature Index Annual Tables. The company experienced a 19% rise in its adjusted share metric, placing it eighth in the global rankings, an advancement from the previous year’s tenth position.

The Nature Index serves as a performance indicator for institutional research. Its primary metric, Share, is a fractional count reflecting the contribution of an institution’s authors to an article.

In the global top ten for life science corporate entities, BGI stands out as the sole representative from the Asia Pacific, alongside six U.S. institutions like Pfizer and three from Europe, including Roche.

Key research contributions from BGI in 2021 encompass significant studies such as “Platypus and Echidna Genomes Reveal Mammalian Biology and Evolution” and “Whole-Genome Resequencing of 445 Lactuca Accessions Reveals the Domestication History of Cultivated Lettuce.”

Founded on September 9, 1999, by a group of young scientists, BGI initially aimed to contribute to the Human Genome Project, targeting the sequencing of approximately 1% of the human genome. Since its inception, BGI has actively collaborated with various international research institutions.

Presently, BGI spearheads international projects like the Ten Thousand Plant Genome Project and the Ten Thousand Bird Genome Project, focusing on sequencing the genomes of 10,000 species of plants and birds. The organization is also engaged in clinical research partnerships emphasizing gene tests with enhanced accuracy and sensitivity.